Peripheral anti-hyperalgesia by oxcarbazepine: involvement of adenosine A1 receptors

Pharmazie. 2006 Jun;61(6):566-8.

Abstract

In this study we determined whether oxcarbazepine (OXC) could produce local peripheral antinociceptive effects in a rat model of inflammatory hyperalgesia, and whether adenosine receptors were involved. When coadministered with the pro-inflammatory compound concanavalin A, OXC (1000-3000 nmol/paw) caused a significant dose- and time-dependent anti-hyperalgesia. Caffeine (1000-1500 nmol/paw), a nonselective adenosine receptor antagonist, as well as 1,3-dipropyl-8-cyclopentylxanthine (DPCPX) (10-30 nmol/paw), a selective A1 receptor antagonist, coadministered with OXC, significantly depressed its anti-hyperalgesic effect. Drugs injected into the contralateral hind paw did not produce significant effects. These results indicate that OXC produces local peripheral anti-hyperalgesic effects, which is mediated via peripheral A1 receptors.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenosine A1 Receptor Agonists
  • Adenosine A1 Receptor Antagonists
  • Animals
  • Anticonvulsants / therapeutic use*
  • Caffeine / pharmacology
  • Carbamazepine / analogs & derivatives*
  • Carbamazepine / therapeutic use
  • Dose-Response Relationship, Drug
  • Drug Synergism
  • Functional Laterality / physiology
  • Hyperalgesia / chemically induced
  • Hyperalgesia / drug therapy*
  • Male
  • Oxcarbazepine
  • Peripheral Nervous System / drug effects*
  • Phosphoric Diester Hydrolases / pharmacology
  • Rats
  • Rats, Wistar
  • Receptor, Adenosine A1 / drug effects*
  • Xanthines / pharmacology

Substances

  • Adenosine A1 Receptor Agonists
  • Adenosine A1 Receptor Antagonists
  • Anticonvulsants
  • Receptor, Adenosine A1
  • Xanthines
  • Carbamazepine
  • Caffeine
  • 1,3-dipropyl-8-cyclopentylxanthine
  • Phosphoric Diester Hydrolases
  • Oxcarbazepine